Elba Pascual-Goñi, Roger Collet, Clara Tejada-Illa, Lorena Martín-Aguilar, Marta Caballero-Ávila, Cinta Lleixà, Silvana Novelli, Jordi López-Pardo, Albert Esquirol Sanfeliu, Anais Mariscal, Yolanda Álvaro Gargallo, Eugenia Martínez-Hernández, Dolores Cocho, Luis Querol
BACKGROUND: Intravenous immunoglobulin (IVIG) and rituximab are considered the first-line and second-line treatments for Chronic Ataxic Neuropathy and Ophthalmoplegia with IgM-paraprotein, cold Agglutinins, and anti-Disialosyl antibodies (CANOMAD), with an overall clinical response around 50%. New anti-CD38 daratumumab, targeting long-lived plasma cells, has been reported as a promising therapy for treatment-refractory antibody-mediated disorders. We report the first case of a severe refractory CANOMAD, successfully treated with daratumumab...
February 10, 2024: Journal of Neurology, Neurosurgery, and Psychiatry